XTX Topco Ltd Invests $352,000 in Anika Therapeutics, Inc. (NASDAQ:ANIK)

XTX Topco Ltd bought a new position in shares of Anika Therapeutics, Inc. (NASDAQ:ANIK - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 21,367 shares of the biotechnology company's stock, valued at approximately $352,000. XTX Topco Ltd owned 0.15% of Anika Therapeutics at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. JPMorgan Chase & Co. raised its stake in shares of Anika Therapeutics by 431.9% in the 4th quarter. JPMorgan Chase & Co. now owns 82,491 shares of the biotechnology company's stock valued at $1,358,000 after acquiring an additional 66,982 shares during the period. Capital Management Corp VA raised its position in Anika Therapeutics by 12.1% in the fourth quarter. Capital Management Corp VA now owns 325,545 shares of the biotechnology company's stock valued at $5,358,000 after purchasing an additional 35,195 shares during the period. ExodusPoint Capital Management LP acquired a new position in Anika Therapeutics during the fourth quarter worth $264,000. Barclays PLC boosted its position in shares of Anika Therapeutics by 66.6% during the third quarter. Barclays PLC now owns 32,664 shares of the biotechnology company's stock worth $806,000 after buying an additional 13,054 shares during the period. Finally, Bank of New York Mellon Corp grew its stake in shares of Anika Therapeutics by 20.8% in the fourth quarter. Bank of New York Mellon Corp now owns 50,529 shares of the biotechnology company's stock valued at $832,000 after buying an additional 8,711 shares in the last quarter. Hedge funds and other institutional investors own 91.53% of the company's stock.

Anika Therapeutics Stock Down 0.2 %

Anika Therapeutics stock traded down $0.03 during midday trading on Tuesday, reaching $14.49. The company's stock had a trading volume of 7,966 shares, compared to its average volume of 69,309. The company has a market cap of $205.34 million, a P/E ratio of -2.18 and a beta of 0.82. The business has a 50-day simple moving average of $15.38 and a 200-day simple moving average of $17.10. Anika Therapeutics, Inc. has a fifty-two week low of $12.83 and a fifty-two week high of $29.12.

Anika Therapeutics (NASDAQ:ANIK - Get Free Report) last issued its earnings results on Wednesday, March 12th. The biotechnology company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.13). The business had revenue of $30.60 million for the quarter, compared to analyst estimates of $29.00 million. Anika Therapeutics had a negative return on equity of 2.22% and a negative net margin of 59.40%. As a group, equities analysts forecast that Anika Therapeutics, Inc. will post -0.84 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have recently weighed in on ANIK shares. Barrington Research cut their price objective on Anika Therapeutics from $25.00 to $20.00 and set an "outperform" rating on the stock in a research report on Thursday, March 13th. StockNews.com upgraded Anika Therapeutics from a "hold" rating to a "buy" rating in a report on Thursday, March 13th. Finally, B. Riley began coverage on Anika Therapeutics in a research report on Thursday, April 17th. They issued a "buy" rating and a $21.00 price target on the stock.

Anika Therapeutics Company Profile

Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.